September 4-5, in Moscow took place the World Health Organization Conference on preventing the restoration of malaria transmission. In a discussion of current issues of malaria elimination in the European Region participated George Ignatiev, Deputy Director for Science Programs in SPbSRIVS. The malaria situation in Russian Federation in not the topic for discussion by public,
Tagged under: , ,

SPbSRIVS took part in IVW 2017

The leading international influenza vaccines conference IVW 2017 is invariably attended by prominent influenza virologists. Mr. John Oxford (founder of influenza vaccinology in the modern sense, pictured), Mr. Peter Palese (expert on universal vaccines), Mr. Ad Osterhaus (expert on prepandemic vaccines against animal flu), Mr. John Wood (expert in biological standardization), Mr. Robert Webster (expert

SPbSRIVS supports applied research

The project “Development of an encapsulation and immobilization technology for multipotent mesenchymal stromal cells and of an inhalation targeted delivery method in the treatment for severe upper respiratory burns” by the Mendeleyev Russian Chemistry and Technology University will be given support by SPbSRIVS. The project has been submitted to the grant contest held as part
It was decided to establish a specialized department of immunobiotechnology directly at the SPbSRIVS production facility. At the meeting of the Academic Council of the St. Petersburg State Chemical and Pharmaceutical Academy (SPCPA), the establishment of the new specialized Department of Immunobiotechnology was unanimously supported by its researchers, and the agreement between the two institutions
250 thousand Nicaraguans will be vaccinated by the Russian vaccine for prevention of influenza produced SPbSRIVS FMBA of Russia. Campaign for vaccination of the elderly was launched in Managua on may 3, 2016. Recall that on 26 April 2016 we have started deliveries of the Russian vaccine for prevention of influenza in Cuba and in Nicaragua.
Tagged under: ,
The new Hib vaccine has been developed from scratch by SPbSRIVS of the Russian Federal Biomedical Agency. Its development, which started less than a year ago, made use of the latest global process aspects of synthesizing similar preparations, among them the processes of cultivation, culture inactivation, purification, and modern methods of control. “Over a short
  NPO Petrovax Pharm was granted official permission by the Russian Ministry of Health to produce a branded flu vaccine Grippol® Plus based on the influenza antigens synthesized at SPbSRIVS of the Russian Federal Biomedical Agency. The two companies’ joint project is being implemented within the framework of the agreement signed in 2015 on long-term